Details

Autor(en) / Beteiligte

• Kobayashi, Kanao
• Takahashi, Satoshi
• Yasuda, Mitsuru
• Miyazaki, Jun
• Wada, Koichiro
• Matsumoto, Masahiro
• Hayami, Hiroshi
• Yamamoto, Shingo
• Kiyota, Hiroshi
• Sato, Junko
• Matsumoto, Tetsuya
• Hasegawa, Naoki
• Kobayashi, Intetsu
• Masumori, Naoya
• Kimura, Takahiro
• Yamada, Hiroki
• Nakagawa, Tohru
• Kaneko, Tomoyuki
• Matsumoto, Kazumasa
• Fujimura, Tetsuya
• Kamei, Jun
• Ishikawa, Kiyohito
• Fujimoto, Kiyohide
• Nakai, Yasushi
• Shigemura, Katsumi
• Sadahira, Takuya
• Hinata, Nobuyuki
• Kitano, Hiroyuki
• Yamashita, Masuo
• Yasufuku, Tomihiko
• Komeda, Hisao
• Hiyama, Yoshiki
• Takahashi, Yoshito
• Kanamaru, Sojun
• Murakami, Masaya
• Arakawa, Soichi
• Yamada, Daisuke
• Mita, Koji
• Hamasuna, Ryoichi
• Tanaka, Kazushi
• Matsukawa, Masanori
• Takaoka, Eiichiro
• Shigeta, Masanobu
• Takenaka, Tadasu
• Nishino, Masashi
• Ishitoya, Satoshi
• Hayakawa, Shohei
• Okumura, Kazuhiro
• Ueda, Masakatsu

Titel

Fourth national Japanese antimicrobial susceptibility pattern surveillance program: Bacterial isolates from patients with complicated urinary tract infections

Ist Teil von

• Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2024-07, Vol.30 (7), p.579-589

Ort / Verlag

Netherlands: Elsevier Ltd

Erscheinungsjahr

2024

Beschreibungen/Notizen

• Antimicrobial susceptibility patterns of bacterial pathogens isolated from patients with complicated urinary tract infections were analyzed using the national surveillance data, comprising 793 bacterial strains from eight clinically relevant species. Data were collected for the fourth national surveillance project from July 2020 to December 2021 by the Japanese Society of Chemotherapy, the Japanese Association for Infectious Disease, and the Japanese Society of Clinical Microbiology. Surveillance was supervised with the cooperation of 43 medical institutions throughout Japan. Fluoroquinolone required a minimum inhibitory concentration (MIC) of 2–64 mg/L to inhibit the 330 tested Escherichia coli strains. The proportion of levofloxacin-resistant E. coli strains increased from 28.6% in 2008 to 29.6% in 2011, 38.5% in 2015, and 44.5% in 2021. The proportion of levofloxacin-resistant strains of Pseudomonas aeruginosa also increased from previous survey results, showing a continuing downward trend. Conversely, the proportion of levofloxacin-resistant strains of Enterococcus faecalis decreased relative to previous reports. Neither multidrug-resistant P. aeruginosa nor carbapenem-resistant Enterobacteriaceae were detected. For methicillin-resistant Staphylococcus aureus (MRSA), the proportion of vancomycin-susceptible strains (MIC of 2 μg/mL) decreased from 14.7% to 7.7%. Bacterial strains that produced extended-spectrum β-lactamase included E. coli (82/330 strains, 24.8%), Klebsiella pneumoniae (11/68 strains, 16.2%), and Proteus mirabilis (4/26 strains, 15.4%). As compared to previous surveillance reports, these strains showed an increase in proportion over the years.